Related Experiment Video
Updated: May 9, 2025
Biosensor for Detection of Antibiotic Resistant Staphylococcus Bacteria
Published on: May 8, 2013
Identification of novel drug targets and small molecule discovery for MRSA infections
Nandha Kumar Subramani1, Subhashree Venugopal1
1School of Bio Science and Technology, Vellore Institute of Technology, Vellore, Tamil Nadu, India.
Introduction:
The topmost deadliest microorganism, namely, methicillin-resistant Staphylococcus aureus (MRSA), causes dreadful infections like bacteremia, pneumonia, endocarditis, and systemic inflammations. The virulence factors associated with MRSA exhibit multidrug-resistant characteristics, complicating treatment choices. So, the primary objective of this study is to identify the MRSA virulence factors and inhibiting its activity utilizing bioinformatic approaches.
Methods:
The screening of novel therapeutic MRSA targets was conducted based on the predictions retrieved from non-homologous, physicochemical analysis, subcellular localization, druggability, and virulence factor examinations. Following that, flavonoid compounds were docked against specific MRSA targets using AutoDock Vina. Further, molecular dynamic simulations and binding free energy calculations were performed using simulation software.
Results:
After examining 2,640 virulence factors that presented in MRSA, the heme response regulator R (HssR) was found to be a novel protein that greatly controls the levels of heme in MRSA infections. Subsequently, the binding energy calculations for flavonoid compounds and HssR revealed that the catechin provided -7.9 kcal/mol, which surpassed the standard drug, namely, vancomycin (-5.9 kcal/mol). Further, the results were validated by evaluating molecular dynamic simulation parameters like RMSD, RMSF, ROG, SASA, and PCA. Through analyzing these parameters, catechin provided a more stable, compact nature and less solvent exposure with HssR than vancomycin. Moreover, the predicted binding free energy for HssR-catechin was found to be -23.0 kcal/mol, which was less compared to the HssR-vancomycin (-16.91 kcal/mol) complex. The results suggested that the catechin was able to modulate the activity of the HssR protein effectively.
Conclusion:
These potential findings revealed that heme response regulator R as a promising therapeutic target while the flavonoid compound catechin could act as alternative therapeutic inhibitor that target MRSA infections.
Insights
This study identifies heme response regulator R as a novel therapeutic target against methicillin-resistant Staphylococcus aureus (MRSA). The flavonoid catechin shows potential as an inhibitor, offering a new strategy for combating MRSA infections.
Area of Science:
- Microbiology
- Computational Biology
- Drug Discovery
Background:
- Methicillin-resistant Staphylococcus aureus (MRSA) is a major cause of severe, multidrug-resistant infections.
- Existing treatments are challenged by MRSA's complex virulence factors.
Purpose of the Study:
- To identify novel MRSA virulence factors as therapeutic targets.
- To discover potential inhibitors for these targets using bioinformatics and molecular modeling.
Main Methods:
- Screening of 2,640 MRSA virulence factors.
- Identification of heme response regulator R (HssR) as a key target.
- Molecular docking and simulations of flavonoid compounds against HssR.
- Binding free energy calculations and molecular dynamics simulations.
Main Results:
- Heme response regulator R (HssR) was identified as a novel virulence factor.
- The flavonoid catechin demonstrated superior binding affinity to HssR compared to vancomycin.
- Molecular dynamics simulations confirmed catechin's stable interaction with HssR.
Conclusions:
- Heme response regulator R is a promising therapeutic target for MRSA.
- Catechin represents a potential alternative therapeutic inhibitor for MRSA infections.
Related Concept Videos
01:26Drug Discovery: Overview
01:26Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...